Clinical Trials
3 trialsNCT03335540 2022-09-26
ADVISE
Bristol-Myers Squibb
Phase 1 Completed
NCT02526017 2022-03-09
FPA008-003
Five Prime Therapeutics, Inc.
Phase 1 Completed
NCT03158272 2020-12-21
A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread
Bristol-Myers Squibb
Phase 1 Completed